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ABSTRACT
Objectives: There is growing evidence that
antihypertensive agents, particularly centrally acting ACE
inhibitors (CACE-Is), which cross the blood–brain barrier,
are associated with a reduced rate of cognitive decline.
Given this, we compared the rates of cognitive decline in
clinic patients with dementia receiving CACE-Is (CACE-I)
with those not currently treated with CACE-Is (NoCACE-I),
and with those who started CACE-Is, during their first
6 months of treatment (NewCACE-I).
Design: Observational case–control study.
Setting: 2 university hospital memory clinics.
Participants: 817 patients diagnosed with Alzheimer’s
disease, vascular or mixed dementia. Of these, 361 with
valid cognitive scores were included for analysis, 85
CACE-I and 276 NoCACE-I.
Measurements: Patients were included if the baseline
and end-point (standardised at 6 months apart)
Standardised Mini-Mental State Examination (SMMSE) or
Quick Mild Cognitive Impairment (Qmci) scores were
available. Patients with comorbid depression or other
dementia subtypes were excluded. The average 6-month
rates of change in scores were compared between CACE-
I, NoCACE-I and NewCACE-I patients.
Results:When the rate of decline was compared
between groups, there was a significant difference in the
median, 6-month rate of decline in Qmci scores between
CACE-I (1.8 points) and NoCACE-I (2.1 points) patients
(p=0.049), with similar, non-significant changes in
SMMSE. Median SMMSE scores improved by 1.2 points
in the first 6 months of CACE treatment (NewCACE-I),
compared to a 0.8 point decline for the CACE-I (p=0.003)
group and a 1 point decline for the NoCACE-I (p=0.001)
group over the same period. Multivariate analysis,
controlling for baseline characteristics, showed
significant differences in the rates of decline, in SMMSE,
between the three groups, p=0.002.
Conclusions: Cognitive scores may improve in the first
6 months after CACE-I treatment and use of CACE-Is is
associated with a reduced rate of cognitive decline in
patients with dementia.
INTRODUCTION
As populations age worldwide, the incidence
of dementia will increase. By 2040,
approximately 81 million people worldwide
will be affected.1 Until now, no agents have
been identified that prevent, modify or
reverse dementia, and available treatments
for dementia are predominantly symptom-
atic.2 There is growing recognition of the
role of cardiovascular risk factors, especially
in midlife, in the conversion and progres-
sion of mild cognitive impairment (MCI)
ARTICLE SUMMARY
Article focus
▪ Treatment options for dementia, including
Alzheimer’s disease, remain limited. The purpose
of this study was to examine the effect of cen-
trally acting ACE inhibitors (CACE-Is) on the rate
of cognitive decline in patients with dementia.
▪ This study also examined the acute effect of
CACE-Is on cognition, during the first 6 months
of treatment.
Key messages
▪ Reduced rates of cognitive decline were seen in an
unselected outpatient sample, prescribed CACE-Is,
irrespective of the blood pressure readings or diag-
nosis of hypertension.
▪ The rate of decline was reduced in patients in the
6 months after starting CACE-Is, compared to
those already established on them.
Strengths and limitations of this study
▪ This study used observational data collected in a
‘real world’ setting, where treatments, including
antihypertensive agents, were administered on
the basis of clinical judgement.
▪ The study investigated the effects of CACE-Is in
an unselected clinic sample of older adults with
different dementia subtypes, whose mean age
approached 80 years.
▪ Although most patients in the database had
Qmci or SMMSE recorded, large numbers lacked
results at the baseline or end point, limiting the
numbers that could be included in the analysis.
▪ Change over 6 months of treatment was ana-
lysed. Different effects may have been demon-
strated over a longer period.
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and dementia.3–5 Blood pressure (BP) control, in par-
ticular, is associated with both a reduced incidence of
cognitive impairment (CI) and rate of cognitive
decline.6–9 Several antihypertensive agents are asso-
ciated with a lower risk of developing dementia, includ-
ing calcium channel blockers (CCBs),10 11 diuretics,8
angiotensin receptor blockers (ARBs)12–14 and ACE
inhibitors (ACE-Is).15 16 ACE-Is and ARBs affect the
renin angiotensin system and may lower dementia risk,
independent of their BP lowering properties.17 Results
of clinical trials investigating the potential role of anti-
hypertensives are limited and conflicting.18 The
Perindopril Protection against Recurrent Stroke Study
(PROGRESS) demonstrated that a combination of peri-
ndopril (ACE-I) and indapamide (diuretic) was asso-
ciated with a significant reduction in the incidence of
stroke and in cognitive decline, compared to placebo.8
The Systolic Hypertension in Europe (Syst-Eur) study
found that the combination of enalapril (ACE-I),
nitrendipine (CCB) and/or hydrochlorothiazide (diur-
etic) reduced the incidence of dementia by 55%, com-
pared to placebo.19 20 Monotherapy with the ARB,
candesartan, in the Study on Cognition and Prognosis
in the Elderly (SCOPE) also showed modest effects.14
Not all studies have shown cognitive benefits with anti-
hypertensive agents; some implicate them in the wor-
sening of cognition.21 The ONTARGET and
TRANSCEND trials, two parallel studies involving more
than 25 000 patients, found that ACE-Is did not have
any measurable effects on cognition.22 Although the
evidence is limited, treatment with antihypertensives
has been associated with reduced rates of cognitive23 24
and functional decline25 in those with established
Alzheimer’s disease (AD).
ACE-Is were one of the first antihypertensives to be
studied, particularly in AD, the most prevalent form of
dementia.26 Patients with AD have abnormal cleavage of
amyloid precursor protein resulting in a pathological
accumulation of amyloid β (Aβ).27 The relationship
between ACE and the accumulation of Aβ is complex
and different polymorphisms have been postulated to
either increase,28 or decrease,29 the risk of developing
AD. ACE activity is increased in AD, proportional to the
Aβ load.30 Centrally acting ACE-Is (CACE-Is) that cross
the blood–brain barrier may have a greater impact than
those that do not. The CACE-I perindopril, administered
to mouse models, showed a significant protective
effect31 and reversed CI more than did the non-centrally
acting imidapril and enalapril.32 Patients receiving
CACE-Is have a reduced rate of cognitive decline com-
pared to both non-centrally acting ACE-Is and CCBs.15
The Cardiovascular Health Study demonstrated no
reduced risk in the incidence of dementia in those
taking CACE-Is compared to other classes of antihyper-
tensives.33 Those prescribed CACE-Is had a reduced rate
of cognitive decline and less impairment in instrumental
activities of daily living compared to those taking non-
centrally acting agents.34 Prescription of ARBs and
ACE-Is is also associated with reduced incidence of both
vascular dementia and mixed dementia subtypes.35 36
Outside of clinical trials, there are few data on the
effects of CACE-Is on the rate of cognitive decline in
patients with dementia. Given this, and the growing evi-
dence for antihypertensive agents, particularly CACE-Is,
in reducing the incidence and rate of cognitive decline,
we compared the rates of decline in patients taking
CACE-Is (called CACE-I) with those not currently pre-
scribed CACE-Is (called NoCACE-I), in those with estab-
lished dementia, attending a memory clinic. We also
examined whether patients started on CACE-Is while
attending clinic (called NewCACE-I), behaved differently
during their first 6 months of treatment, compared to




Data were analysed from the Geriatric Assessment Tool
(GAT) database, a customised software application that
automates physicians’ clinic assessments. Data were col-
lected in memory clinics in two university hospitals in
Ontario, Canada. The database contains over 8000 indi-
vidual assessments from 1749 people aged 41–104 years.
GAT data, collected between 1999 and 2010, includes
age, gender, education, medical diagnosis, BP, laboratory
findings, medications, etc and the scores of two cogni-
tive screening tests, the Standardised Mini-Mental State
Examination (SMMSE)37 38 and the Quick Mild
Cognitive Impairment (Qmci) screen,39 40 a new cogni-
tive screen, more sensitive and specific for differencing
MCI from normal cognition and dementia than the
SMMSE.39 Both tests were administered to patients by
trained raters (clinic nurses) blind to the diagnosis,
prior to each assessment, to monitor progression.
The Qmci has six subtests covering five cognitive
domains: orientation, working memory, semantic
memory (verbal fluency for animals), visual spatial
(clock drawing) and two tests of episodic memory
(delayed recall and immediate recall logical memory). It
is scored out of 100 points.
Subjects
Patients with dementia were diagnosed by a consultant
geriatrician using NINCDS41 and the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria.42 Only patients with AD, vascular or
mixed dementias (Alzheimer’s/vascular) were included
in this analysis. As there is little evidence that antihyper-
tensive medications affect other dementia subtypes,
patients with Parkinson’s disease dementia,43 44 fronto-
temporal dementia,45 Lewy body dementia,46 alcohol-
related dementia, post-trauma and post-anaesthetic
dementia were excluded. Patients with MCI, n=235,
defined as those with subjective and corroborated
memory loss, without obvious loss of function,47 were
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excluded. Patients with MCI were excluded because few,
n=12, had baseline and end-point Qmci scores available.
Although the SMMSE was available, it is insensitive to
MCI,39 and rates of cognitive decline vary, depending on
the cognitive measures used.48 Patients with normal cog-
nition, n=181 and depression, n=397 were also excluded.
Participants were screened for depression using the
15-point Geriatric Depression Scale.49 As there is limited
evidence that ACE-Is affect comorbid depression,50 while
depression negatively affects the results of cognitive
testing,51 397 participants with depression were
excluded: 260 with CI and comorbid depression and 137
with normal cognition and depression. Patients with
depression were predominantly (63%) women and were
significantly younger than patients without depression,
mean age 72.7 (SD 10.7), p<0.001. Patients were also
excluded if they did not have the results of either the
Qmci or SMMSE available at both the baseline and end
point. Changes between the baseline and end-point (last
visit) scores were standardised at 6 months to facilitate
comparison between all groups. In total, 56% (n=456)
of patients with dementia did not have the same cogni-
tive test recorded at two visits and were therefore
excluded. Regression analysis, adjusting for baseline
characteristics (age, gender, education and BP) between
participants without follow-up and those included,
showed no significant difference in baseline SMMSE
(p=0.06) or Qmci scores (p=0.51). Patient selection is
presented graphically in figure 1. The CACE-I group
included patients currently prescribed the following
CACE-Is: perindopril, ramipril, trandolapril, captopril,
fosinopril, lisinopril, prinivil and monopril.34 52
Figure 1 Flow chart demonstrating the breakdown of the patients included in the Geriatric Assessment Tool (GAT) database.
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NoCACE-I included patients who were not currently
receiving CACE-Is, irrespective of the BP readings, diag-
nosis of hypertension or whether they were receiving
other antihypertensive medications.
Analysis
Our goal was to determine whether there were differ-
ences in rates of change, from the baseline to the end
point (the time point when cognitive scores were last
available), in Qmci and SMMSE scores between patients
in the NoCACE-I, NoCACE-I and NewCACE-I groups
while attending clinic. Given that regulatory authorities
like the US Food and Drug Administration require evi-
dence of change in cognitive tests over 6 months41 53 to
confirm benefit from new medications, we used change
scores from the baseline, on a six-monthly basis, accord-
ing to the formula:
Rate of decline ¼ (Baseline score end - point score)
 6=duration in months
We also used multivariate regression to compare end-
point cognitive scores (SMMSE and Qmci), adjusted for
the baseline cognitive scores and characteristics (age,
years of education, duration of follow-up and BP),
between the three groups (CACE-I, NoCACE-I and
NewCACE-I). Data were analysed using SPSS V.18.0. The
Kolmogorov-Smirnov and Shapiro-Wilk tests were used
to test for normality. Non-normally distributed data were
compared with the Mann-Whitney U test. Categorical
data were analysed with χ2 tests.
RESULTS
Baseline characteristics
In total, there were 817 patients with dementia. Of
these, 361 with SMMSE and Qmci scores recorded at
two or more visits were included for analysis, 85 receiv-
ing CACE-Is and 276 receiving NoCACE-Is. The mean
age of those included was 77.9 years with an SD of
8.1 years. Half (50.3%) were men and the mean time
spent in education was 11.2 years. The mean age of
patients taking CACE-Is was 77.2 years compared to
77 years for the NoCACE-Is group. Men represented
51.8% of the CACE-I group compared to 49.6% of the
NoCACE-I group. Within the NoCACE-I group, 30 parti-
cipants had been started on ACE-Is while attending
clinic (NewCACE-I). Table 1 shows the baseline charac-
teristics, including demographics and medication use,
for the CACE-I, NoCACE-I or NewCACE-I groups.
Both SMMSE and Qmci scores were available for 147
participants at the baseline and end point, while 206
participants had SMMSE scores only and 8 had Qmci
scores alone. For the participants included, the mean
SMMSE scores at the baseline and end point were 21.6
(SD±5.6) and 18.1 (SD±8.0), respectively. Mean Qmci
scores were 36.8 (SD±13.6) and 31.3 (SD±18.3), respect-
ively. Table 2 presents the baseline and end-point Qmci
and SMMSE scores for the CACE-I, NoCACE-I or
NewCACE-I groups. After adjusting for the baseline char-
acteristics (age, education, duration of follow-up and
BP), there were no significant differences in the baseline
cognitive scores (SMMSE and Qmci) between the three
groups (CACE-I, NoCACE-I and NewCACE-I).
In relation to medications, 88.2% of the CACE-I group,
82.6% of the NoCACE-I group and 80% of those in the
NewCACE-I group were receiving cholinesterase inhibi-
tors (CholEIs). A smaller percentage was currently pre-
scribed memantine. There was no difference in the
distribution of CholEIs (p=0.40) or memantine (p=0.98)
between the CACE-I, NoCACE-I and NewCACE-I groups.
Rate of decline
The median change in SMMSE scores between the base-
line and end point for those included was 0.69 points
per 6 months (IQR of 2). The median SMMSE score dif-
ferences for the CACE-I, NoCACE-I and NewCACE-I
groups were 0.8, 1.0 and −1.2, respectively, per
6 months. For the Qmci, the median change was 2
points per 6 months, with median Qmci score differ-
ences for the CACE-I and NoCACE-I groups of 1.8 and
2.1, respectively, per 6 months.
There was a small but non-significant difference in the
SMMSE median rate of decline over 6 months for
patients taking CACE-Is, compared to NoCACE-I
patients, p=0.77. The difference in the median rates of
Table 1 Baseline characteristics of CACE-I, NoCACE-I or NewCACE-I patients
Groups CACE-I NoCACE-I NewCACE-I
Number 85 276 30
Age (mean±SD) 77.2±6.4 77.0±7.6 77.3±8.2
Male (%) 44 (51.8) 137 (49.6) 15 (50)
Education (mean±SD) 10.6±3.8 11.4±4.0 12.1±3.9
Systolic BP in mm Hg (mean±SD) 133.4±21.2 135.5±16.9 141.1±16.2
Diastolic BP in mm Hg (mean±SD) 70.1±12.6 72.5±11.5 78.1±17.0
Cholinesterase inhibitor use (%) 75 (88.2) 228 (82.6) 24 (80)
Memantine use (%) 23 (27.1) 72 (26.1) 8 (26.7)
BP, blood pressure; CACE-I, patients currently receiving ACE inhibitors; NewCACE-I, patients who were newly started on CACE-Is;
NoCACE-I, patients who are not currently prescribed CACE-Is.
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decline in Qmci scores reached borderline significance,
p=0.049. The median decline in scores (rate per
6 months) for the NewCACE-I group, on the SMMSE,
was −1.2 points for the NewCACE-I group, significantly
less than for the CACE-I group (median 0.8); p=0.003
and NoCACE-I group (median 1.0), p=0.001. The Qmci
could not be compared for the NewCACE-I group, as
the numbers were too small. These results are presented
in table 3. Multivariate regression analysis was used to
compare the end-point cognitive scores (SMMSE and
Qmci), adjusting for baseline cognitive scores (SMMSE
and Qmci) and patient characteristics (age, education,
duration of follow-up and BP). There were significant
differences in end-point scores for the SMMSE
(p=0.002) between all three groups (CACE-I, NoCACE-I
and NewCACE-I). No significant difference was seen, for
the Qmci, comparing the CACE-I and NoCACE-I
groups, (p=0.172).
CONCLUSION
This study demonstrates a small reduction in the rate
of cognitive decline, measured with the SMMSE and
Qmci, in patients taking CACE-Is compared to the
NoCACE-I group. The changes in Qmci scores over
6 months were small but statistically significant. The
SMMSE scores, while non-significant, suggested a
possible slower progression among those currently
receiving CACE-Is. NewCACE-I patients, started on
CACE-Is while attending clinic, showed a median
improvement rather than a decline in SMMSE scores,
over the first 6 months of treatment, compared to those
already taking CACE-Is and those not currently treated
with CACE-Is. These results confirm an association
between the use of CACE-Is, particularly during the
first 6 months of treatment, and a reduced rate of cog-
nitive decline. This is the first study to demonstrate that
cognitive scores improve in patients starting on
CACE-Is, compared to those already established on
maintenance treatment. This may have been related to
better medication compliance, the effects of improved
BP control or increased cerebrovascular perfusion after
initial treatment.54 55
The strength of the study lies in its large numbers and
inclusion of different (AD, vascular and mixed) demen-
tia subtypes. The study also investigates the effects of
CACE-Is in an unselected clinic sample of older adults,
whose mean age approached 80 years. It has a number
of limitations. This study is an analysis of observational
data collected in a ‘real world’ setting, where treatments,
including antihypertensive agents, were administered on
the basis of clinical judgement. Observational studies
like this are subject to bias in that those who receive
treatment may be systematically different from those
Table 3 Comparison of differences in Qmci and SMMSE scores between baseline and end point
Groups
Mann-Whitney
U test (p Values)
Changes in Qmci CACE-I (53) vs NoCACE-I (102) 0.049
median = 1.8* vs median = 2.1*
Changes in SMMSE CACE-I (113) vs NoCACE-I (240) 0.77
median = 0.8* vs median = 1.0*
NewCACE-I (30) vs NoCACE-I (240) 0.001
median =−1.2* vs median = 1.0*
NewCACE-I (30) vs CACE-I† (83) 0.003
median =−1.2* vs median = 0.8*
*Median score shows the change in six months for CACE-I, NoCACE-I and NewCACE-I
†CACE-I group excluding NewCACE-I patients.
CACE-I, patients currently receiving ACE inhibitors; NewCACE-I, patients who were newly started on CACE-Is; NoCACE-I, patients who are
not currently prescribed CACE-Is; Qmci, Quick Mild Cognitive Impairment; SMMSE, Standardised Mini-Mental State Examination.













SMMSE CACE-I 83 77.3 (±6.6) 53 17 (34–7) 22 (25–19) 20 (25–14)
NoCACE-I 270 77.1 (±7.6) 49.3 18 (31–9) 23 (26–19) 20 (25–13)
NewCACE-I 30 77.3 (±8.2) 50 6 (7–4) 23 (27–18) 24 (27–19)
Qmci CACE-I 41 78.9 (±6.1) 56.1 16 (31–7) 36 (44–23) 29 (49–15)
NoCACE-I 114 78.0 (±7.6) 49.1 11 (24–6) 38 (47–27) 32 (45–17)
CACE-I, patients currently receiving ACE inhibitors; NewCACE-I, patients who were newly started on CACE-Is; NoCACE-I, patients who are
not currently prescribed CACE-Is; Qmci, Quick Mild Cognitive Impairment; SMMSE, Standardised Mini-Mental State Examination.
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who do not. That said, the baseline demographic charac-
teristics of the groups were similar and few participants,
in the NewCACE-I group, received other medications
that could have accounted for the differences observed.
Compliance with antihypertensive treatment, which has
been shown to reduce with time,56 57 could also have
been a confounding factor and may have accounted for
the improvement in the NewCACE-I group. Similarly,
duration of treatment with antihypertensive medications,
prior to attending clinic, could not be established for
the CACE-I and NoCACE-I groups in this retrospective
analysis.
Although most patients in the database had a Qmci or
SMMSE recorded, large numbers lacked results at the
baseline or end point, limiting the numbers that could be
included in the analysis. It is possible that the results
would have differed with more complete data on all
patients. However, the baseline cognitive scores were
similar between those included and excluded because of
missing data. In the comparison of the subgroup scores,
change over the first 6 months of treatment was analysed
as this is the accepted time scale to show evidence of
benefit in clinical drug trials.53 Although a small percent-
age (9%) had a shorter interval between the baseline
and end-point scores, the duration of follow-up was stan-
dardised at 6 months to facilitate comparison. The
accepted standard for measuring cognitive change is the
ADAS-cog.58 As this was an observational study in a clinic
setting, only the Qmci and the commonly used SMMSE
were available. The ADAS-cog is not an ideal test59 and
the Qmci has been shown to be as sensitive to change as
its standardised version, the SADAS-cog.60 Significant dif-
ferences, between NewCACE-I and the other groups’
scores, using the SMMSE, could not be replicated with
the Qmci, as the numbers were too small to analyse.
In summary, this study demonstrates an association
between the use of CACE-Is and reduced rates of cogni-
tive decline, in an unselected sample of clinic patients
with dementia, particularly in the first 6 months of treat-
ment. This supports the growing body of evidence for
the use of ACE-Is and other antihypertensive agents in
the management of dementia.18 Although the differ-
ences were small and of uncertain clinical significance,
if sustained over years, the compounding effects may
well have significant clinical benefits. However, this may
be tempered by recent evidence suggesting that ACE-Is,
by interfering with degradation of Aβ, could contribute
to increased amyloid burden,61–63 potentially accelerat-
ing dementia severity and rates of cognitive decline.34
Indeed, ACE-Is may even increase mortality in patients
with CI, suggesting that if ACE-Is are proven to be bene-
ficial in dementia, not all patients will benefit.64 Further
study with an appropriately powered randomised trial is
needed to confirm these findings and determine if and
for how long these effects are sustained.65 If these data
can be reproduced in a randomised trial of sufficient
length incorporating appropriate outcome measures,
such as an amyloid positron emission tomography, then
these agents are likely to have significant benefits in
delaying or even preventing dementia.
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